What's Going On With Viking Therapeutics Stock On Wednesday?
What's Going On With Viking Therapeutics Stock On Wednesday?
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
周三，默沙东（纽交所：MRK）与中国生物制药公司翰森制药签署了一项关于HS-10535的全球独家许可协议，该药物是一种研究中的临床前口服小分子GLP-1受体激动剂。
Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the candidate's development, regulatory approval, and commercialization, as well as royalties on sales.
根据协议，翰森制药已授予默沙东独家全球许可，以开发、制造和商业化HS-10535。翰森制药将获得11200万美金的预付款，并有资格获得高达19亿美金的与候选药物开发、监管批准和商业化相关的里程碑付款，以及销售的特许权使用费。
Also Read: Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
另请阅读：Viking Therapeutics获得分析师对NASH和代谢项目的支持
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.
翰森制药可以在中国共同推广或单独商业化HS-10535。默沙东将在2024年第四季度记录11200万美金的税前费用，此费用将包含在GAAP和非GAAP结果中，每股费用为0.04美金。
William Blair writes that Merck is seen as a strong candidate to acquire Viking Therapeutics Inc (NASDAQ:VKTX), leading to an expected sell-off in Viking shares. However, the analyst notes that the licensing agreement with Hansoh will not hinder Merck from pursuing additional external business development opportunities in the obesity space.
威廉·布莱尔表示，默沙东被视为收购Viking Therapeutics Inc（纳斯达克：VKTX）的强有力候选者，这导致预计Viking股票会被出售。然而，分析师指出，与翰森的许可协议不会阻止默沙东追求在肥胖领域的其他外部业务发展机会。
The licensing deal highlights Merck's commitment to obesity, potentially driving further growth through additional partnerships. While the focus on Viking increases investment volatility, data from competitors or new licensing deals could significantly affect its stock.
这项许可交易突显了默沙东对肥胖问题的承诺，可能通过额外的合作推进进一步的增长。虽然对Viking的关注增加了投资波动性，但竞争对手的数据或新的许可交易可能会显著影响其股票。
William Blair remains confident that Viking offers a valuable asset with VK2735, a GLP-1/GIP dual agonist that could become a major player in obesity treatment due to its potential for monthly maintenance dosing and oral formulation options.
威廉·布莱尔对Viking以VK2735这一GLP-1/GIP双激动剂作为有价值资产的观点保持信心，认为其由于每月维持剂量和口服制剂选项的潜力，可能成为肥胖治疗的重要参与者。
This asset could strengthen an acquiring company's obesity portfolio, with additional potential from Viking's amylin program.
这一资产可能增强收购公司的肥胖投资组合，并为Viking的淀粉酶项目提供额外潜力。
Overall, the analyst is optimistic about Viking's prospects, maintaining the stock as a top pick for 2025 and an Outperform rating on its shares.
总体来看，分析师对Viking的前景持乐观态度，保持该股票为2025年的首选，并对其股票给予超越大盘的评级。
Price Action: VKTX stock is down 11.4% at $41.37 at last check Wednesday.
价格走势：VKTX股票周三最后检查时下跌了11.4%，报41.37美元。
- Renewable Energy Company Ørsted Sells 50% Stake In US Solar And Battery Projects For $572 Million: Details
- 可再生能源公司Ørsted以57200万美元出售其在美国的太阳能和电池项目50%的股份：详情
Photo via Shutterstock.
图片来自shutterstock。
译文内容由第三方软件翻译。
